Oppenheimer F, Rebollo P, Grinyo JM, Ortega F, Sanchez-Plumed J, Gonzalez-Molina M, Hernandez D, Anaya F, Ekberg H
Health-related quality of life of patients receiving low-toxicity immunosuppressive regimens: a substudy of the Symphony study. [Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't]
Transplantation 2009 Apr 27; 87(8):1210-3.
OBJECTIVE: To evaluate health-related quality of life (HRQoL) in patients with different low-toxicity regimens posttransplantation.
METHODS: One hundred fifty-six patients were randomized to standard-dose cyclosporine A (CsA), mycophenolate mofetil, and corticosteroids or daclizumab induction, mycophenolate mofetil, and corticosteroids with a low dose of CsA, tacrolimus (Low-Tac), or sirolimus. SF-36 Health survey was completed at baseline, 3, 6, and 12 months.
RESULTS: There were no differences between groups in SF-36 at baseline or at month 12. Low-Tac showed higher scores at month 3 than standard-dose CsA and low dose of CsA. Patients with serum creatinine less than or equal to 1.5 mg/mL had better HRQoL at 6 and 12 months. Proportion of these patients was higher in Low-Tac at 6 months. Physical component summary of Patients increased during follow-up, but mental component summary did not. Patients with acute rejection showed lower mental component summary at 6 months.
CONCLUSIONS: No HRQoL differences were identified among groups, but the low-dose Tac group showed the fastest improvement.
More from this journalRelated subjects (MeSH) |
